In conclusion, NCALD reduction in hiPSC-derived MNs increases neuronal activity, and supports the results obtained in the preclinical study, where the combination of SMN- and Ncald-ASOs ameliorate electrophysiological defects in SMA mice. The gene discussed is NCALD; the disease is proximal spinal muscular atrophy.